STUDY QUESTION: Is the presence of polycystic ovary syndrome (PCOS) associated with anogenital distance (AGD), a biomarker for the prenatal hormonal environment?
Introduction
Polycystic ovary syndrome (PCOS), a common endocrine disorder in adolescents and young women, is characterized by the presence of at least two of the following criteria: polycystic ovaries, hyperandrogenism and chronic anovulation (Rotterdam PCOS Consensus Workshop Group, 2004) . PCOS affects 5-10% of woman during their reproductive period (Franks, 1995; Rotterdam PCOS Consensus Workshop Group, 2004; March et al., 2010; Li et al., 2013) . Affected women suffer from irregular menses, infertility, hirsutism and metabolic complications, which constitute a considerable burden regarding physical and psychological health (Jones et al., 2008) .
Although the aetiology of PCOS is poorly understood, there is increasing evidence suggesting that prenatal exposure to androgen hormones is an important factor (Abbott et al., 2002 (Abbott et al., , 2005 Homburg, 2009) . Previous studies in animal models have identified that PCOSlike phenotypes (i.e. increased LH secretion, hyperandrogenaemia, oligoovulation, polycystic ovary (PCO) and metabolic abnormalities) can be produced by prenatal androgenization (Sullivan and Moenter, 2004; Abbott et al., 2005; Recabarren et al., 2005; Wu et al., 2010) . In a remarkable series of experiments, Abbott et al. (2005) induced a phenotype distinctly resembling that of PCOS in prenatally androgenized female rhesus monkeys and found that the phenotype of PCOS differed according to the timing of the start of androgenization. In sheep, testosterone-treated prenatally, Vasantha Padmanabhan's group also generated a PCOS-like phenotype, and the authors proposed that disruptions initiated by excess prenatal testosterone create a self-perpetuating vicious cycle leading to PCOS (Veiga-Lopez et al., 2013) . Clinical observations also support a potential foetal origin of PCOS. Women with foetal androgen excess disorders, including congenital adrenal hyperplasia (CAH) or congenital adrenal virilizing tumours, have an increased incidence of PCOS during adulthood, despite the normalization of androgen excess with treatment or removal of the tumour after birth (Merke and Cutler, 2001, Stikkelbroeck et al., 2003a,b) .
The anogenital distance (AGD) is the distance measured from the anus to the genital tubercle. There is considerable evidence in humans and animal models supporting AGD as a sensitive biomarker of prenatal androgen action and a reflection of reproductive health (McIntyre et al., 2001; Wolf et al., 2004; Thankamony et al., 2016) . In animals, AGD is approximately twice as long in males compared to females, and it is routinely used to determine sex (Dean and Sharpe, 2013) . Although lacking precise AGD measurements, Abbott reported that virilized genitalia was an obvious sign in prenatal testosteronetreated female rhesus monkeys and the virilized genitalia can only be induced during early gestation (Abbott et al., 2005) . Similarly, it has been shown that early prenatal testosterone treatment can result in virilization of external genitalia in female sheep (Veiga-Lopez et al., 2013) . In rat models, male offspring showed decreased AGD when exposed to antiandrogens in utero (McIntyre et al., 2001) . In another study, female offspring of rats given testosterone propionate during pregnancy demonstrated increased AGD (Wolf et al., 2004) . Studies in human have also shown alterations in AGD associated with reproductive health. For example, significantly shorter AGD has been reported in boys with hypospadias and cryptorchidism (Hsieh et al., 2008 (Hsieh et al., , 2012 Thankamony et al.,2014) , and men with poorer semen quality (Eisenberg et al., 2011; Mendiola et al., 2011) or reduced testicular volume have significantly shorter AGD compared with controls. In women, increased AGD has been reported in girls with CAH, which is associated with conditions of hyperandrogenism (Callegari et al., 1987) . Similarly, newborn daughters of women with PCOS had significantly longer AGD AF (from the posterior fourchette to the centre of the anus) compared with daughters of women without PCOS (Barrett et al., 2016) . In addition, Mendiola et al. (2016) found that shorter AGD in women was associated with the presence of endometriomas and deep infiltrating endometriosis, which has been hypothesized to be aetiologically correlated to exposure to oestrogen in utero.
However, to the best of our knowledge, no study to date has investigated the relationship between AGD and PCOS. We hypothesized that a prenatal androgenic environment, resulting in a relatively longer AGD, will be associated with a higher risk of PCOS. The aim of this study was to assess the relationship between AGD and the presence of PCOS in adulthood.
Materials and Methods

Study population
Eligible patients were women with PCOS attending the out-patient Department of Gynecology at the Sun Yat-sen Memorial Hospital from October 2015 to July 2016, including on-going and newly diagnosed cases. The following criteria were necessary for participation in the study: (i) aged 18-35 years old; (ii) diagnosis of PCOS according to the Rotterdam 2003 criteria (Rotterdam PCOS Consensus Workshop Group, 2004 ) briefly a diagnosis of PCOS requires fulfilment of at least two of the following three criteria: (a) hyperandrogenism either clinical (a modified Ferriman-Gallwey (mF-G) score (Ferriman and Gallwey, 1961 ) ≥6 (Ichikawa et al., 1988) , with/without acne, and/or androgenic alopecia) or biochemical (total testosterone (T) level ≥2.6 nmol/l); (b) chronic oligoanovualtion; (c) polycystic ovaries on pelvic ultrasound examination, and exclusion of most rare androgen excess disorders (androgen-secreting neoplasm, hyperprolactinemia, Cushing's syndrome, nonclassic adrenal hyperplasia, thyroid dysfunction); (iii) not pregnant; (iv) no history of vaginal delivery or having oncological treatment or genitourinary prolapse; (v) no smoking or drinking; (vi) no history of medication within the previous 3 months, including oral contraceptives, ovulation induction agents, or oestrogenic, antiandrogenic medication. The controls were healthy women who underwent routine exams within the same period, and fulfilled the following criteria: (i) aged 18-35 years old; (ii) regular menstrual cycles (28-35 days); (iii) no clinical evidence of hyperandrogenism or menstrual disturbances; (iv) not pregnant; (v) no history of vaginal delivery or having oncological treatment or genitourinary prolapse; (vi) no smoking or drinking; (vii) no history of medication within the previous 3 months, including oral contraceptives, ovulation induction agents, or oestrogenic, antiandrogenic medication. We initially invited 175 PCOS patients and 211 healthy women; of these, 166 PCOS patients and 193 healthy women met the inclusion criteria and agreed to participate in our project. Among these women, 156 patients and 180 healthy women attended the clinical appointments, with the exclusion of one control woman with extreme hormone concentrations (FSH and LH >2 standard deviations of the mean value). Written informed consent was obtained from all subjects. This study was approved by the Ethics Research Committee of Sun Yat-sen Memorial Hospital, Sun Yat-sen University.
Anthropometric and hormonal measurements
All study participants underwent anthropometric parameter measurements. Body height and weight were measured using a digital electronic scale. BMI was calculated as weight in kilograms divided by the square of height in metres.
The women were asked to lay down in the lithotomy position with their thighs at 45°to the examination table. A digital caliper (Stainless Steel Digital Caliper, GuangLu ® , Guilin Guanglu Measuring Instrument Co., Ltd, Guilin, China) was used to measure AGD AC and AGD AF . Two gynaecologists who were blind to the gynaecological status of the women measured each distance three times, and the mean value of the six measurements of each AGD was used. AGD AC was measured from the anterior clitoral surface to the centre of the anus, and AGD AF was measured from the posterior fourchette to the centre of the anus (Fig. 1 ). All blood samples were collected in the morning after the women had fasted for at least 8 h, and on the same day of the clinical appointment and during the early follicular phase (the first 5 days of spontaneous menstrual cycles or if ultrasonography did not reveal large follicles (diameter > 9 mm)). T, FSH and LH levels were measured by chemiluminescence (ACS180 SE, Bayer, Germany).
Statistical analyses
Normality of continuous variables was confirmed by Kolmogorov-Smirnov test, and the means are presented with the SD. Continuous variables were compared using Student's t-test, and categorical variables were compared using x 2 tests. We assessed intra-and inter-examiner variability in AGD measurements using coefficients of variation (%CV). Multiple linear regression analyses were used to identify predictors of each of the two AGD measurements. The covariates initially examined as predictors of AGD measurements were age, height, weight, BMI, age at menarche and sexual history (yes/no). We used multiple logistic regression to examine the association between the presence of PCOS (yes/no) and AGD (in tertiles from the entire distribution of the PCOS group and controls, with the lowest tertile as the reference category) using odds ratios (ORs). Multiple linear regression analyses were applied to identify the association between the characteristics of PCOS (the presence of PCO and serum reproductive hormone levels of T, FSH and LH) and AGD measurements in the PCOS group and controls. All tests were two-tailed, and P < 0.05 was considered statistically significant. The statistical analysis was performed using SPSS 13.0 (SPSS, Chicago, IL, USA).
Results
In total, 180 controls and 156 PCOS patients, who met the inclusion and exclusion criteria, were recruited. Table I shows the general characteristics of the controls and PCOS patients. The intra-and inter-examiner % CV for both AGD measurements were <5 and 10%, respectively.
Controls and PCOS cases were similar with regard to age (P = 0.080), BMI (P = 0.161), age at menarche (P = 0.494) and FSH (P = 0.343), but AGD AC , AGD AF , LH and T were higher (P < 0.001) in the PCOS cases (means ± SD, Control versus PCOS: AGD AC , 97.1 ± 9.4 versus 104.9 ± 9.1 mm; AGD AF , 22.0 ± 3.7 versus 26.6 ± 4.0 mm; LH, 5.5 ± 2.4 versus 10.9 ± 4.7 IU/l;T, 1.5 ± 0.5 versus 2.3 ± 0.9 nmol/l). AGD AC and AGD AF were correlated (Pearson's correlation (r) = 0.56, P < 0.001) in the entire population. Multivariate analyses revealed a significant positive association between age and both AGD measurements (β = 0.112 for AGD AC , β = 0.146 for AGD AF ; P = 0.023 and P = 0.019, respectively), and BMI was associated with longer AGD (β = 0.476 for AGD AC , β = 0.511 for AGD AF ; both P < 0.001). We included age (years) and BMI (kg/m 2 ) as covariates in the subsequent statistical analyses. Twentythree of the controls had polycystic ovaries without any symptoms, and two had biochemical hyperandrogenism.
Overall, AGD measurements were correlated with the presence of PCOS in the adjusted models, in which women with AGD AF in the highest tertile had 18.8 times (95% CI 9.6-36.6; P < 0.05) greater odds of having PCOS compared with those in the lowest tertile (Table II) . However, the strength of the association decreased when the analysis examined AGD AC . Woman with AGD AC in the highest tertile had 6.7 times (95% CI 3.7-12.1; P < 0.05) greater odds of developing PCOS than those in the lowest tertile. The relationship between the characteristics of PCOS with AGD measurements in both groups examined by the multiple linear regression analyses is presented in Table III. In the PCOS group, T levels were associated with longer AGD (β = 0.246 for AGD AC , β = 0.368 for AGD AF ; P = 0.003 and P < 0.001, respectively). LH levels and the presence of polycystic ovaries were significantly associated with longer AGD AF (β = 0.187and β = 0.279; P = 0.001 and P < 0.001, respectively). In the controls, a positive association was only found for the T levels and AGD AF (β = 0.177, P = 0.020), and no associations were found between the remaining covariates and AGD measurements.
Discussion
This is the first study to measure AGD in women with PCOS. A positive association between AGD and T levels was identified in these patients. Furthermore, we found a strong association between AGD AF and the presence of PCOS, suggesting that the intrauterine hormonal milieu during prenatal life may play an important role in the development of PCOS.
PCOS shows a peripubertal onset and familial clustering. However, the genotype and phenotype of this syndrome lacks a reliable association (Dumesic et al., 2007) , indicating that environmental factors may also contribute to PCOS. Experimental animal research studies have demonstrated that foetal exposure to excess androgen can induce a PCOS-like phenotype in adult life (Abbott et al., 2002; Xita and Tsatsoulis, 2006; Franks, 2012; Ramezani Tehrani et al., 2014) . Moreover, the phenotype of PCOS can differ according to the timing of the start of androgenization (Abbott et al., 2005) . Thus, it has been hypothesized that the aetiology of PCOS may include excess prenatal androgen exposure. In a study by Hart's group, maternal testosterone levels within the normal range did not predict PCOS in offspring (Hickey et al., 2009) , and the authors considered that placental aromatase can protect the foetus from maternal androgens, thus, placental dysfunction, which can expose the foetus to higher concentrations of androgens, may be the cause of PCOS. In our study, we were unable to measure the exact testosterone level in utero or to value the placental function. Nonetheless, the idea that the anogenital index reflects prenatal exposure to androgens has been supported by a number of studies, and we demonstrated an association between AGD and the presence of PCOS. There is considerable evidence in humans and animal models that AGD acts as a sensitive biomarker of prenatal androgen action and that it reflects reproductive health. Rodent studies have demonstrated that AGD is determined by androgen exposure within a narrow masculinization programming window (MPW), indicating that prenatal exposure to androgens has more profound effects on genital length than postnatal insults (Welsh et al., 2008; Macleod et al., 2010; van den Driesche et al., 2011) . AGD can be easily and inexpensively measured, although lacking systematical research, the time that AGD examination takes for one individual each time was preliminarily calculated to be no more than 30 s in our study. It has been shown that AGD is stable across the woman's menstrual cycle (Barrett et al., 2015) and appears to be stable in early childhood for both males and females (Thankamony et al., 2009 ). In a cross-sectional study of 473 adult men with a mean age of 43 ± 13 years, AGD was found to have similar values in different age groups (Eisenberg et al., 2013) . While in our study, age was associated with longer AGD measurements, suggesting that AGD may not remain constant across early adulthood. However, confirmation with longitudinal studies is needed. BMI was also associated with longer AGD according to our multivariate analyses. Thus, we included age and BMI as covariates in the analyses. The use of hormonal contraception has been reported to be associated with shorter AGD measurements (Mendiola et al., 2012) . In theory, contraception suppresses androgen secretion and reduces the serumfree androgen, which may result in alterations in AGD. We excluded women with a history of hormone medication within the previous 3 months, as well those with a history of vaginal delivery, oncological treatment or genitourinary prolapsed, as these factors can affect AGD (Bump et al., 1996) . In our study, BMI was similar in the PCOS and control groups, and a similar result was found in one large-scale study of PCOS patients in China . Although the abdominal phenotype of obesity may be partly responsible for insulin resistance and associated hyperinsulinaemia in women with PCOS, BMI is generally lower in PCOS patients in China than in PCOS patients from western countries, particularly patients in southern China (Chen et al., 2010) .
Our study showed that PCOS patients have longer AGD compared with controls, and a significant association between the presence of PCOS and increased AGD was observed, which indicate that the PCOS might have a prenatal origin. Prenatal exposures may affect the development of the reproductive tract, which in turn is associated with later onset of adult diseases. In a recent study, longer AGD AF in young woman was associated with irregularities in the menstrual cycles of their mothers prior to pregnancy (Mira-Escolano et al., 2014a) , suggesting that the prenatal environment may exert a long-lasting effect on the reproductive tract of female offspring. Similarly, Barrett et al. (2016) reported that newborn daughters of women with PCOS had significantly longer AGD AF compared with daughters of women without PCOS and suggested that AGD may be a potential marker of the downstream risk of PCOS. Another anatomical marker of intrauterine hyperandrogenism, as judged by a lower ratio of the index (2D) to ring (4D) finger, was also investigated for a relationship with PCOS. Indeed, Cattrall et al. (2005) found a significant difference in the right hand 2D:4D of women with severe forms of PCOS compared with healthy woman controls. Conversely, no such difference was found in the study by Lujan et al. (2010) , which comprised a more varied PCOS population, and the authors concluded that the 2D:4D ratio may represent a weak measure of prenatal androgen exposure that cannot reflect differences in PCOS. We also found a significant association between AGD and the presence of PCOS. However, as an observational study, the findings cannot provide causal inference, and further studies with a larger population are needed to confirm these preliminary findings.
In this study, 75.6% of the PCOS group displayed the PCO phenotype, and there was a significant positive association with the presence of PCO and AGD AF in PCOS. In a cross-sectional study of healthy young women, Mendiola et al. (2012) similarly reported that AGD measurements were positively associated with the ovarian follicle number. In that study, the cutoff for a multifollicular ovary was defined as '≥6 follicles per ovary'. In our study, PCO was defined as '≥12 follicles in either ovary', and the association was further confirmed in PCOS, which could suggest common foetal origins for elevated prenatal testosterone levels and follicular development in PCOS. Indeed, in female rodents increased follicular recruitment can be induced by androgen exposure in utero (Wu et al., 2010) . A study by Hart et al. identified a similar effect of prenatal androgens in humans, reporting increased serum anti-Müllerian hormone (AMH), a marker for the presence of PCO (Hart et al., 2010a) , in adolescent daughters exposed antenatally to high levels of androgens (Hart et al., 2010b) . In our study, PCO was present in 12.8% of the control group, though we did not identify an association between the presence of PCO and AGD in the controls. As woman with PCO are only a small proportion of the normal community, studies with a larger population of healthy women with PCO are necessary to identify a relationship.
A significant positive association with the T levels and AGD measurements was reported in a previous study of healthy women (Mira-Escolano et al., 2014b). We also found a positive association with the T levels and AGD AF in the controls and further confirmed this finding in PCOS patients, which could indicate that longer AGD and a higher level of T may share a common foetal hyperandrogenic environment in PCOS. In previous animal models studies, masculinization of the AGD was only observed when exogenous androgen exposure occurred during the presumptive MPW both in female rhesus monkeys (Abbott et al., 2005) and in rats (Welsh et al., 2008) . Thus, the effect of excess androgen in PCOS may already be operating in the prenatal period. Homburg et al. proposed that excess androgens begin influencing the foetus via altering in gene expression, thereby producing symptoms that are then exacerbated by excess androgen production from multiple small follicles, resulting in a vicious perpetual cycle of androgen excess in PCOS (Homburg, 2009) . In their hypothesis, androgen excess is the root of PCOS.
In PCOS cases, we found a significant association only for AGD AF with the presence of PCO; there was also a significant association for AGD AF with the presence of PCOS, whereas that for AGD AC was less strong. Other studies have reported similar findings with regard to associations with a short (equivalent) measurement (anus-scrotum) (Eisenberg et al., 2011; Mendiola et al., 2011; Mira-Escolano et al., 2014b) . The reason for this result is currently unclear. However, as AGD could be a clinically relevant measure for PCOS, with potential clinical value for evaluating reproductive health, it would be advisable to take both AGD measurements as they can be easily and inexpensively acquired.
Conclusion
Our results provide the first evidence of a strong association between the presence of PCOS and a biomarker of the hormonal prenatal environment in women. The current findings are consistent with studies that indicate PCOS may originate in intrauterine life and be affected by prenatal exposure to androgens. Due to the difficulty in measuring human foetal androgen levels during gestation, it is advisable to explore the potential clinical value of AGD. Further studies are warranted to corroborate these findings and to provide new insights into the aetiology of PCOS.
